TY - JOUR
T1 - Identification and characterization of NanH2 and NanH3, enzymes responsible for sialidase activity in the vaginal bacterium Gardnerella vaginalis
AU - Robinson, Lloyd S.
AU - Schwebke, Jane
AU - Lewis, Warren G.
AU - Lewis, Amanda L.
N1 - Funding Information:
This work was supported by NIAID, National Institutes of Health Grants AI114635 and AI127554 (to W. G. L and A. L. L.) and the Burroughs Well-come Fund (BWF) Preterm Birth Initiative (to A. L. L.). A. L. L. has had con-sulting relationships with Talis Biomedical Corporation (2018), Tennor Therapeutics (2016), and Toltec Pharmaceuticals (2017). A. L. L. and W. G. L. have performed contract research for Metis Therapeutics (2017). A. L. L., W. G. L., and L. S. R. have an ongoing research project funded by Metrodora Therapeutics (2018–2019). Although all of these relationships pertain to our specific expertise on bacterial vaginosis, none are directly related to the specific topics or assays of interest in this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
This work was supported by NIAID, National Institutes of Health Grants AI114635 and AI127554 (to W. G. L and A. L. L.) and the Burroughs Wellcome Fund (BWF) Preterm Birth Initiative (to A. L. L.). A. L. L. has had consulting relationships with Talis Biomedical Corporation (2018), Tennor Therapeutics (2016), and Toltec Pharmaceuticals (2017). A. L. L. and W. G. L. have performed contract research for Metis Therapeutics (2017). A. L. L., W. G. L., and L. S. R. have an ongoingresearch project funded by Metrodora Therapeutics (2018 2019). Although all of these relationships pertain to our specific expertise on bacterial vaginosis, none are directly related to the specific topics or assays of interest in this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2019 Robinson et al.
PY - 2019/4/5
Y1 - 2019/4/5
N2 - Gardnerella vaginalis is abundant in bacterial vaginosis (BV), a condition associated with adverse reproductive health. Sialidase activity is a diagnostic feature of BV and is produced by a subset of G. vaginalis strains. Although its genetic basis has not been formally identified, sialidase activity is presumed to derive from the sialidase A gene, named here nanH1. In this study, BLAST searches predicted two additional G. vaginalis sialidases, NanH2 and NanH3. When expressed in Escherichia coli, NanH2 and NanH3 both displayed broad abilities to cleave sialic acids from 2-3- and 2-6-linked N- and O-linked sialoglycans, including relevant mucosal substrates. In contrast, recombinant NanH1 had limited activity against synthetic and mucosal substrates under the conditions tested. Recombinant NanH2 was much more effective thanNanH3 in cleaving sialic acids bearing a 9-O-acetyl ester. Similarly, G. vaginalis strains encoding NanH2 cleaved and foraged significantly more Neu5,9Ac2 than strains encoding only NanH3. Among a collection of 34 G. vaginalis isolates, nanH2, nanH3, or both were present in all 15 sialidase-positive strains but absent from all 19 sialidase-negative isolates, including 16 strains that werenanH1-positive.We concludethatNanH2 andNanH3 arethe primary sources of sialidase activity in G. vaginalis and that these two enzymes can account for the previously described substrate breadth cleaved by sialidases in human vaginal specimens of women with BV. Finally, PCRs of nanH2 or nanH3 from human vaginal specimenshad 81% sensitivity and 78% specificityindistinguishing between Lactobacillus dominance and BV, as determined by Nugent scoring.
AB - Gardnerella vaginalis is abundant in bacterial vaginosis (BV), a condition associated with adverse reproductive health. Sialidase activity is a diagnostic feature of BV and is produced by a subset of G. vaginalis strains. Although its genetic basis has not been formally identified, sialidase activity is presumed to derive from the sialidase A gene, named here nanH1. In this study, BLAST searches predicted two additional G. vaginalis sialidases, NanH2 and NanH3. When expressed in Escherichia coli, NanH2 and NanH3 both displayed broad abilities to cleave sialic acids from 2-3- and 2-6-linked N- and O-linked sialoglycans, including relevant mucosal substrates. In contrast, recombinant NanH1 had limited activity against synthetic and mucosal substrates under the conditions tested. Recombinant NanH2 was much more effective thanNanH3 in cleaving sialic acids bearing a 9-O-acetyl ester. Similarly, G. vaginalis strains encoding NanH2 cleaved and foraged significantly more Neu5,9Ac2 than strains encoding only NanH3. Among a collection of 34 G. vaginalis isolates, nanH2, nanH3, or both were present in all 15 sialidase-positive strains but absent from all 19 sialidase-negative isolates, including 16 strains that werenanH1-positive.We concludethatNanH2 andNanH3 arethe primary sources of sialidase activity in G. vaginalis and that these two enzymes can account for the previously described substrate breadth cleaved by sialidases in human vaginal specimens of women with BV. Finally, PCRs of nanH2 or nanH3 from human vaginal specimenshad 81% sensitivity and 78% specificityindistinguishing between Lactobacillus dominance and BV, as determined by Nugent scoring.
UR - http://www.scopus.com/inward/record.url?scp=85064398467&partnerID=8YFLogxK
U2 - 10.1074/jbc.RA118.006221
DO - 10.1074/jbc.RA118.006221
M3 - Article
C2 - 30723162
AN - SCOPUS:85064398467
SN - 0021-9258
VL - 294
SP - 5230
EP - 5245
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 14
ER -